About

Benjamin Shepherd is a recognized exchange-traded fund (ETF), mutual fund and stock expert with an extensive background analyzing time-tested funds, including their managers and strategies. Ben looks for investments that have proven themselves in both bull and bear markets. Ben also specializes in covering emerging markets, pinpointing the most dynamic investments in developing nations for market-beating growth.

Ben is an analyst for Global Income Edge and regularly contributes to Personal Finance, Investing Daily's flagship product.

Content from Benjamin Shepherd

Inflation Hedges: Gold & REITs
Benjamin Shepherd

With inflation consistently hitting new highs, now's the time to buy some insurance. Below, we explore the right inflation hedg...

Tickers: GLD | IAU | O | VNQ
Robotics: A New Machine Age
Benjamin Shepherd

President Trump believes that too many jobs are being shipped overseas to take advantage of cheaper labor. But what's mainly ki...

Tickers: ABB | CGNX
HiMax: Value in Virtual Reality"
Benjamin Shepherd

Industry analysts predict that within a decade, virtual reality (VR) will become the fastest-growing technology niche, with ann...

Tickers: HIMX
Office REITs: Brandywine & Starwood
Benjamin Shepherd

With interest rates near all-time lows, investors are looking for replacement income, and REITs continue to offer higher yields...

Tickers: BDN | STWD
Bel Fuse: The Nuts and Bolts
Benjamin Shepherd

Uncovering undervalued stocks can be as simple as sifting through those most analysts ignore. To find them, I screen out compan...

Tickers: BRLFB
Investing in Cuba
Benjamin Shepherd

Regardless of what you might think about Cuba's politics, thawing U.S.-Cuban relations are creating the potential for big profi...

Tickers: CPA
Glaxo: Advair to Zika
Benjamin Shepherd

Despite concerns over patent expirations, we continue to recommend this UK-based pharmaceutical stock based on its dividend and...

Tickers: GSK
GalxoSmithKline: Cash Cow in Pharma
Benjamin Shepherd

Benjamin Shepherd reviews a recommended healthcare firm that has faced slow growth and patent expirations; here, the editor of...

Tickers: VRTX